Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.95 USD

91.95
548,324

+0.45 (0.49%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $92.05 +0.10 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3

OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.

    Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?

    On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).

      Is Baxter Poised to Counter Low Cyclophosphamide Sales?

      On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

        CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions

        On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).

          Alere (ALR) Appeals to Reinstate Medicare Billing Privilege

          Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.

            NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite

            NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.

              LabCorp: Covance Drug Prospects Bright, Competition Rife

              On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).

                ResMed: SDB Business Faces Risks, Reimbursement a Drag

                On Dec 27, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).

                  Nutrisystem Declares Multi-Brand Marketing Approach for '17

                  Nutrisystem Inc. (NTRI) announced that it will focus on a multi-brand marketing approach with two new distinct programs.

                    Myriad Genetics' Unit Releases Favorable Data on Vectra DA

                    Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).

                      Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger

                      On Dec 27, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).

                        Haemonetics' Plasma Group Impresses, Blood Center a Drag

                        On Dec 12, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE).

                          Haemonetics Introduces Upgraded NextGen DMS 4 Software

                          Haemonetics Corporation (HAE) recently unveiled upgraded NextGen DMS (Donor Management System) to augment plasma collection center operations.